Adjuvance Overview
- Founded
-
2009

- Status
-
Out of Business
- Employees
-
18

- Latest Deal Type
-
Out of Business
Adjuvance General Information
Description
Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine adjuvant. The company's platform is based on SAPONEX products that are critical components to many vaccines for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy, enabling patients to improve their immune systems.
Contact Information
Website
www.adjuvancetechnologies.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1225 L Street
- Suite 600
- Lincoln, NE 68508
- United States
Adjuvance Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Out of Business | 20-Apr-2022 | 000.00 | Completed | Out of Business | ||
6. Grant | 19-May-2020 | 00.000 | 000.00 | Completed | Pre-Clinical Trials | |
5. Later Stage VC (Series A1) | 29-Jan-2020 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
4. Grant | 01-Jan-2020 | 00000 | 00.00 | Completed | Pre-Clinical Trials | |
3. Seed Round | 29-Aug-2019 | 00.00 | 00.00 | Completed | Pre-Clinical Trials | |
2. Grant | 01-Mar-2017 | $1.5M | Completed | Pre-Clinical Trials | ||
1. Grant | 01-Jan-2017 | $448K | Completed | Pre-Clinical Trials |
Adjuvance Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Adjuvance Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details

Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine a
Drug Discovery
Lincoln, NE
18
As of 2022
000.00
00000000 00
000.00
Adjuvance Competitors (3)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Dynavax Technologies | Corporation | Emeryville, CA | 000 | 00000 | 000000000 | 00000 |
0000000 | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
000000000000000 00 | Corporation | Saint-Amand-Les-Eaux, France |
Adjuvance Patents
Adjuvance Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020379738-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
CA-3157372-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
US-20220409721-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
EP-4054616-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
US-20200261571-A1 | Triterpene saponin analogues | Active | 16-Oct-2017 | A61P37/04 |